Genomic classifier (GC) tests do not appear to consistently influence risk classification or treatment decisions for patients with newly diagnosed prostate cancer considering first-line treatment, ...
Tests do not consistently influence risk classification or treatment decisions; authors call for well-designed trials on role of GC tests in newly diagnosed PCa. (HealthDay News) — For patients with ...
Differences in Health Care Use and Costs Among Patients With Cancer Receiving Intravenous Chemotherapy in Physician Offices Versus in Hospital Outpatient Settings With increased demand for hereditary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results